Article Text

Detection of myositis-specific antibodies: additional notes
  1. Michael Mahler1,
  2. Marvin J Fritzler2
  1. 1Department of Research, Inova Diagnostics, San Diego, California, USA
  2. 2Department of Medicine, Health Sciences Centre, University of Calgary, Calgary, Alberta, Canada
  1. Correspondence to Dr Michael Mahler, Department of Research, INOVA Diagnostics, San Diego, CA 92131, USA; mmahler{at}

Statistics from

With interest we read the recent article by Vulsteke et al1 showing data derived from an evaluation of three immunoassay systems for the detection of autoantibodies associated with autoimmune inflammatory myopathies (AIM). As stated by the authors, careful evaluation of autoantibody assays for the detection of myositis-specific (MSA) and myositis-associated (MAA) antibodies is of utmost importance since some of these are included or being considered for the AIM classification criteria.2–4 The biomarkers are also relevant for establishing the diagnosis and stratification into specific disease subsets.

The authors compared the performance of three test systems and used primarily clinical diagnoses and features as comparators. In the interests of assay evaluation and standardisation, it is valuable to also provide data showing a more comprehensive statistics-based approach for method comparison. However, this …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.